Oral Colchicine in Argentina to Prevent Restenosis
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The Oral treatment of Colchicine in Argentina (ORCA) trial is a prospective, randomized,
multicenter trial to included 450 patients with indication for myocardial revascularization
with PCI between a group to be treated with BMS plus oral colchicine (OC) for three months,
which should be administered at the time of PCI, these patients they would receive 0.5 mg
twice a day per 3 months compared to the other group of patients who will be treated
exclusively with last generation of DES.
Phase:
Phase 4
Details
Lead Sponsor:
Centro de estudios en Cardiologia Intervencionista